Key Takeaways
- • Webster Equity Partners agreed to acquire Lifecore Biomedical in a take-private transaction valued at up to approximately $663.7 million, contingent on full achievement of specified performance milestones, with a definitive agreement signed on September 28, 2026.
- • Common shareholders will receive $6.28 per share in cash at closing plus one nontradable contingent value right (CVR) per share, with CVRs providing up to $160 million in aggregate cash payments upon satisfaction of performance milestones.
- • Lifecore, a fully integrated injectables contract development and manufacturing organization (CDMO) based in Chaska, Minnesota, specializing in sterile injectable drug development and fill-finish services, will remain operationally independent under Webster's ownership, retaining its headquarters, name, and brand.
- • Webster Equity Partners, a Waltham, Massachusetts–based private equity firm focused on healthcare services, structures the transaction as a classic middle-market PE take-private with a cash floor plus milestone-linked upside for shareholders.
- • Transaction closing is expected in the fourth quarter of 2026, subject to stockholder approval and regulatory clearance.
Summary
Webster Equity Partners has secured a definitive agreement to acquire Lifecore Biomedical for up to approximately $663.7 million, marking a significant healthcare sector consolidation in the contract development and manufacturing space. The agreement was announced on September 28, 2026, according to GlobeNewswire and Goodwin client disclosures. Lifecore, headquartered in Chaska, Minnesota, operates as a fully integrated injectables CDMO, providing specialized services in the development, fill-finish, and manufacturing of sterile injectable drugs across syringes, vials, and cartridges.
The transaction structure reflects a conventional private equity playbook: common shareholders receive $6.28 per share in immediate cash consideration at closing, supplemented by nontradable contingent value rights (CVRs) that unlock additional value upon achievement of specified performance milestones. The CVR component carries up to $160 million in aggregate potential cash payments, representing meaningful upside exposure for shareholders confident in Lifecore's operational trajectory. Series A preferred stockholders will receive their applicable conversion amount in cash at closing plus CVRs calculated on the basis of their convertible common share equivalents, preserving preferential economics through the take-private process.
Webster Equity Partners, a middle-market healthcare-focused private equity firm based in Waltham, Massachusetts, intends to maintain Lifecore's operational independence following the acquisition. The company will retain its Minnesota headquarters, brand identity, and corporate name—a commitment that underscores Webster's strategy to preserve existing management and operational frameworks rather than pursue immediate integration or rebranding. This operational posture is typical for PE acquisitions in specialized manufacturing segments where customer relationships and regulatory certifications are tied to established entity structures.
The transaction is expected to close during the fourth quarter of 2026, subject to customary stockholder approval and regulatory clearance. For healthcare PE investors and public-to-private specialists, the transaction benchmarks include the September 28 definitive agreement date, the $6.28 per-share cash floor, the $160 million CVR ceiling, and the up-to-$663.7 million all-in valuation assuming full milestone achievement. The milestone-contingent structure reflects both PE confidence in Lifecore's near-term performance trajectory and recognition of operational or market execution risks inherent in the injectables CDMO sector.
The transaction structure reflects a conventional private equity playbook: common shareholders receive $6.28 per share in immediate cash consideration at closing, supplemented by nontradable contingent value rights (CVRs) that unlock additional value upon achievement of specified performance milestones. The CVR component carries up to $160 million in aggregate potential cash payments, representing meaningful upside exposure for shareholders confident in Lifecore's operational trajectory. Series A preferred stockholders will receive their applicable conversion amount in cash at closing plus CVRs calculated on the basis of their convertible common share equivalents, preserving preferential economics through the take-private process.
Webster Equity Partners, a middle-market healthcare-focused private equity firm based in Waltham, Massachusetts, intends to maintain Lifecore's operational independence following the acquisition. The company will retain its Minnesota headquarters, brand identity, and corporate name—a commitment that underscores Webster's strategy to preserve existing management and operational frameworks rather than pursue immediate integration or rebranding. This operational posture is typical for PE acquisitions in specialized manufacturing segments where customer relationships and regulatory certifications are tied to established entity structures.
The transaction is expected to close during the fourth quarter of 2026, subject to customary stockholder approval and regulatory clearance. For healthcare PE investors and public-to-private specialists, the transaction benchmarks include the September 28 definitive agreement date, the $6.28 per-share cash floor, the $160 million CVR ceiling, and the up-to-$663.7 million all-in valuation assuming full milestone achievement. The milestone-contingent structure reflects both PE confidence in Lifecore's near-term performance trajectory and recognition of operational or market execution risks inherent in the injectables CDMO sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.